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Patients with congestive heart failure and Cheyne-Stokes respiration have a low arterial oxygen saturation, especially 
during sleep, which can be increased by breathing oxygen. Chronic alterations in blood gases are known to modulate 
the hypercapnic ventilatory response (HCVR). We therefore evaluated whether the HCVR is influenced by 
nocturnal nasal oxygen in patients with heart failure and Cheyne-Stokes respiration. 
Twenty patients with chronic congestive heart failure and a left ventricular ejection fraction ~35% (mean 
18.3% f SD 6.0%) as well as 25 healthy control subjects were studied. The patients were assigned to 1 week each of 
nocturnal nasal oxygen and room air with a flow of 4 1 min - i in a randomized cross-over fashion. After each week 
resting ventilation and HCVR were evaluated by the rebreathing technique. 
Breathing oxygen during the night for 1 week increased the basal nocturnal oxygen saturation from 92.5% & 1.6% 
to 96.5% f 0.9% (P<O*OOO 01) and reduced Cheyne-Stokes respiration. HCVR was 1.22 * 0.90 1 min- ’ mmHg- ’ 
after nocturnal room air and did not differ from that in the control subjects (1.31 & 0.62 1 min - ’ mmHg - ‘). In the 
patients HCVR decreased to 0.91 & 0.52 1 min - i mmHg - i after nocturnal oxygen (P=O.O19). There were no 
significant changes with nocturnal oxygen in resting minute ventilation, respiratory rate or end-tidal PCO,. 
We conclude that nocturnal nasal oxygen reduces HCVR in patients with congestive heart failure and 
Cheyne-Stokes respiration. 
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Introduction 
Patients with severe congestive heart failure exhibit a 
ventilation-perfusion mismatch and rapid, shallow breath- 
ing due to decreased lung compliance as well as activation 
of pulmonary receptors or some other non-CO,-dependent 
central neural drive (1,2) with concomitantly increased 
minute ventilation and reduced PaCO, (34). A substantial 
proportion of patients with heart failure exhibit nocturnal 
Cheyne-Stokes respiration (CSR) with prominent oxygen 
desaturations (4-6). 
It is known that chronic hypercapnia decreases the 
hypercapnic ventilatory response (HCVR) (7). Hypoxia as 
well as hypocapnia, on the other hand, increase HCVR (8). 
These alterations in ventilatory control may persist some 
hours after return to normoxia and normocapnia (7,9). 
Reversal of the mild hypoxia and an increase in PaCO, 
with nocturnal oxygen might therefore reduce the HCVR in 
patients with congestive heart failure. A low HCVR is 
related to an enhanced stability of the feedback loop 
controlling ventilation and less hyperventilation during 
exercise in patients with chronic heart failure (10,ll). Thus, 
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nocturnal oxygen could be expected to reduce nocturnal 
CSR and might have long-term clinical benefits such as 
improved exercise tolerance. The present study was 
designed to examine the influence of 1 week of nocturnal 
nasal oxygen on the HCVR in these patients. 
Subjects and Methods 
SUBJECTS AND PROTOCOL 
The patients presented here took part in a previously 
published study evaluating the influence of nocturnal nasal 
oxygen on sleeping respiration, exercise tolerance and cog- 
nitive function in patients with congestive heart failure (12). 
Patients under the age of 75 years were eligible for the study 
if they met the following criteria: at least one episode of 
cardiac decompensation, ejection fraction I 35%, stable 
clinical condition on cardiac medications which in all cases 
included a vasodilator or angiotensin-converting enzyme 
inhibitor and CSR during sleep. Exclusion criteria were 
significant obstructive lung disease as defined by FEV,/ 
FVC <65%, myocardial infarction within 1 yr of entry, 
tibia1 oedema and evidence of pulmonary oedema or of 
obstructive sleep apnoea. Medications consisted of a 
diuretic in 19 patients, an angiotensin-converting enzyme 
inhibitor in 18 patients, /3-acetyldigoxin in 17 patients and a 
vasodilator in seven patients. No changes in any of these 
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medications were made during the study. One patient had 
a cerebral infarction 1 yr previously. Twenty-five healthy 
subjects with normal lung function tests served as the 
control group. The study was approved by the local ethics 
committee. Informed written consent was obtained from all 
subjects. 
The study followed a randomized, cross-over protocol. 
The patients were advised to measure their weight every day 
and to adhere to fluid restriction in order to keep their body 
weight stable during the study period. Nasal nocturnal 
oxygen and room air were administered through nasal 
prongs at a flow rate of 4 1 min - ’ for seven nights. Oxygen 
and room air were provided by two different air compres- 
sors (Heinen & Lowenstein, Germany). Oxygen through 
nasal prongs increases the inspiratory oxygen concentration 
to 2530%. During the seventh night polysomnography was 
performed. Arterial oxygen saturation was measured 
transcutaneously on the tip of the index finger by pulse 
oximetry (Micro Span 3040G). The data were stored on an 
optical disc via a commercially available computer system 
(CNS sleep laboratory, lOOO/AMPs). The polysomnogram 
was visually analysed in 30 s epochs for sleep stages (12). 
CSR was considered to be present when there were at least 
three regular cycles of increasing and decreasing airflow as 
well as increasing and decreasing thoracic and abdominal 
efforts. The cycle periods and the transit times between the 
increase in ventilation and the nadir in arterial oxygen 
saturation during CSR were averaged over the whole night. 
For every cycle the minimal and maximal arterial oxygen 
saturation was measured. Minute ventilation and end-tidal 
PCO, were measured and the rebreathing test was per- 
formed on the morning of the eighth day of either room air 
or oxygen. 
CO, REBREATHING 
HCVR was evaluated postprandially in the morning by the 
rebreathing method. For at least 5 min respiratory rate, 
minute ventilation and end-tidal PCO, were measured 
while the subject was breathing room air in a seated 
position with the eyes closed. Minute ventilation was nor- 
malized for body surface area (13). Thereafter the subject 
rebreathed into a 10 1 bag with 60% oxygen resulting in a 
gradual increase in end-tidal PCO, while minute ventilation 
and respiratory rate were measured with a low-resistance 
pneumotachograph (A Fleisch, Switzerland). End-tidal 
PCO, and oxygen concentration were monitored con- 
tinuously by withdrawing expired gas from the mouth- 
piece (Datex Normocap, Helsinki, Finland). The slopes 
of minute ventilation-end-tidal PCO, and respiratory 
frequency-end-tidal PCO, relationships were determined 
by linear least-squares regression analysis and represent the 
ventilatory and frequency responses respectively to PCO,. 
The ventilatory response (HCVR) was normalized for body 
surface area (13). 
In 14 patients PaCO, was measured transcutaneously 
while they breathed room air or oxygen during wakefulness 
in the supine position with the eyes closed. We did not 
perform this measurement overnight since the probe and 
the underlying skin are heated to 45°C which can cause mild 
discomfort and therefore may impair sleep. The transcu- 
taneous capnograph (TCM3, Radiometer, Copenhagen, 
Denmark) was calibrated with 5% carbon dioxide. Fresh 
bicarbonate solution was inserted around the pH electrode 
and a new oxygen- and carbon-dioxide-permeable mem- 
brane was used for each study. The sensor was placed on 
the anterior chest wall and heated to 45°C. Measurements 
began after a period of at least 15 min when the recording 
was stable, and arterial blood samples were analysed (ABL 
3, Radiometer, Copenhagen, Denmark) for in vivo calibra- 
tion. PaCO, was then recorded during room air and oxygen 
breathing as described above and averaged over 30 min. 
Spirometry was performed. Vital capacity, forced expira- 
tory volume in 1 s and diffusion capacity for carbon mon- 
oxide are given as percentages of the predicted value 
(14,15). In the patient group left ventricular end-diastolic 
and left atria1 diameter were evaluated by echocardio- 
graphy. Left ventricular ejection fraction at rest was 
determined by 99Tcm gated blood pool scintigraphy. 
STATISTICAL ANALYSIS 
All variables were tested for normal distribution (16) and 
are given as mean * standard deviation. The effect of 
oxygen was evaluated using the two-tailed Student t test for 
paired data. Comparison with the control group was per- 
formed with the two-tailed Student t test for unpaired data. 
All calculations were performed on a personal computer 
using the statistical package NCSS (Number Cruncher 
Statistical System Version 5.x 1989, by J. L. Hintze, North 
Kaysville, UT). A P value ~0.05 was considered significant. 
Results 
Four patients had coronary artery disease and I6 had 
idiopathic dilated cardiomyopathy. Three were in New 
York Heart Association class II and 17 in class III. They 
slept with one or two pillows but no patient was orthop- 
noeic. One patient was female. Two patients exhibited atria1 
fibrillation. One patient had a cerebral infarction 1 yr 
previously. Eleven patients received room air and nine 
patients oxygen during the first week of the study. Mean 
runtime of the concentrators was 7.1 * 1.5 h day-’ with 
room air and 7.3 i 1.2 h day ~ ’ with oxygen (P not signifi- 
cant). Two patients in each of the two treatment groups 
gained more than 1 kg body weight over the course of 
the study. The weight of the other patients remained 
stable. The patients’ left ventricular ejection fraction was 
183% + 6.0% (range 1 l-35%), the left atria1 diameter was 
50 + 5 mm (normal ~40 mm) and the left ventricular end- 
diastolic diameter was 74 * 7 mm (normal <56 mm). The 
patients exhibited a restrictive pattern on lung function 
tests, the minute ventilation at rest was increased and 
end-tidal PCO, was reduced when compared with normal 
subjects (Table 1). The basal SaO, during sleep was 
92.5% 5 1.6% with room air and 96.5% i 0.9% with oxygen 
(P<O.OOO 01). The time during which SaO, was below 90% 
as a percentage of total sleep time was 184% f 18.6% and 
0.5% f 1.1% respectively (P<O.O002). Nocturnal oxygen 
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TABLE 1. Pulmonary function data of the patients and the control group 
Patients Control 
(n=20) (n=25) P 
Age (years) 
Body surface area (m2) 
VC (% predicted) 
FEV, (% predicted) 
FEV,NC (%) 
Transfer factor for CO (% predicted) 
MV/BSA (1 min - ’ m - ‘) 
End-tidal PCO, (mmHg) 
Respiratory rate (min - ‘) 
HCVR (1 min ~ ’ mmHg - ‘) 
HCFR (min - ’ mmHg - i) 
HCVR/BSA (1,min - i mmHg - ’ - m 2, 
58* 10 54f 10 0.21; NS 
1.94 zt 0.22 1.99 Z!T 0.23 0.42; NS 
80% 16 96* 11 0.0003 
82 I!Z 22 101 f 15 0.002 
78iLll 81&6 0.28; NS 
82 f 22 104* 11 0~0001 
7.9 f 1.9 6.1 * 1.1 0.0003 
33.5 f 57 38.0 f 3.3 0.004 
14.3 * 1.5 13.1 + 3.4 0.13; NS 
1.22 + 0.90 1.31 * 0.62 0.71; NS 
0.36 III 0.53 0.23 f 0.15 0.30; NS 
0.64 f 0.51 0.65 zt 0.29 0.93; NS 
VC, vital capacity; FEV,, forced expiratory volume in 1 s; MV, minute ventilation; BSA, body 
surface area; HCVR, hypercapnic ventilatory response; HCFR, hypercapnic frequency response. 
significantly reduced the duration of CSR corrected for 
total sleep time by about 50% from 50%& 58% to 
21%+ 20% (P<O.O05) and the mean oxygen desatura- 
tion during CSR from 10.2% f 6.4% to 2.1% Y! 1.8% 
(P<O.OOOl). Transit time was 41.2 f 17.8 s and did not 
change with nocturnal oxygen. 
In the 14 patients in whom PaCO, was measured trans- 
cutaneously while awake SaO, was higher while breath- 
ing oxygen as compared with room air (97.6% f 0.8% 
KS. 94.7% & 1.2%; P<O.OOOl) and PaCO, increased from 
38.4 & 4.4 to 40.2 f 5.6 mmHg (PcO.01). End-tidal and 
transcutaneous PaCO, were not investigated simul- 
taneously. The mean difference (transcutaneous minus 
end-tidal) between both methods was 3.8 & 3.7 mmHg for 
the patients and 4.0 & 1.4 mmHg for the controls. 
In patients breathing room air HCVR did not differ from 
the controls (Table 1). In all but three patients HCVR 
decreased following a week of nocturnal oxygen (Fig. 1). 
This decrease was positively correlated with the HCVR 
evaluated after room air (rz0.87; P<O.OOOl) but not with 
the increase in basal oxygen saturation with oxygen. The 
HCVR corrected for body surface area was not significantly 
correlated with ejection fraction (r=0.003; P=O.99); left 
ventricular end-diastolic diameter (r=0.17; P=O.49) or vital 
capacity as a percentage of predicted (r= - 0.14; PzO.36). 
Minute ventilation, respiratory rate and end-tidal PCO, at 
rest did not change with nocturnal oxygen (Table 2). 
Discussion 
Nocturnal nasal oxygen decreased the HCVR in our 
patients with congestive heart failure (Table 2). This may be 
attributed to the nocturnal increase in oxygen saturation 
and PaCO, with nasal oxygen. These patients with severe 
heart failure previously had mild nocturnal hypoxia over at 
least several months which was reversed with oxygen treat- 
ment. This situation is similar to that previously reported 
for patients with hypoxaemia due to a chronic arterio- 
venous fistula where the HCVR was attenuated after 
closure of the fistula with concomitant reversal of the 
hypocapnic hypoxaemia (17). Correspondingly, chronic 
hypercapnia (breathing 1.5% CO,) decreases the HCVR (7) 
and chronic isocapnic hypoxia [PaO, about 50 mmHg (S)] 
as well as hypocapnia [PaCO, about 30 mmHg (8)] 
increases the HCVR in normal subjects. When compared 
with these studies, however, the changes in blood gases 
observed in our patients were small, with a mean increase in 
arterial oxygen saturation of 3.9% and in PaCO, of about 
2 mmHg. 
I P = 0.019 
I 
0  
0 
0 t 
Room air Oxygen 
FIG. 1. Hypercapnic ventilatory response after room air 
and oxygen. Individual data for all 20 patients as well as 
mean and SD are given. 
TABLE 2. Change of parameters with nocturnal oxygen 
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Room air Oxygen P 
End-tidal PCO, (mmHg) 33.5 -f 5.1 34.2 zt 6.6 0.81; NS 
MV (1 min - ‘) 15.3 i 3.1 15.0 i 5.1 0.58; NS 
Respiratory rate (min - ‘) 14.9 * 3.6 14.1 f 4.0 0.45; NS 
HCVR (1 min - ’ mmHg - ‘) 1.22 f 0.90 0.93 f 0.52 0.019 
HCFR (min - * mmHg - ’ ) 0.31 f 0.54 0.29 f 0.35 0.84; NS 
Abbreviations as in Table 1. 
We did not evaluate the HCVR during sleep when the 
changes in blood gases were actually present, rather when 
the patients had been breathing room air for l-2 h. This 
means that the effects we observed were of a more chronic 
than acute nature. While the ventilatory effects of acute 
changes in blood gases have been the subject of a number of 
previous studies, the ventilatory response to chronic altera- 
tions in blood gases is not well characterized (18). Low- 
landers during a 45 day sojourn at high altitude have an 
increased ventilatory response that is reversed with return 
to sea level (19). After 3-5 days of hypoxia at high altitude, 
deacclimatization of ventilation and acid-base status takes 
more than 1 day (9). Similar deacclimatization from chronic 
CO, inhalation for over 5 weeks (in a submarine) lasts 3 
weeks (7). The longer the initial acclimatization period the 
more time is needed for complete restoration of normal 
respiratory control. The process underlying deacclimatiza- 
tion is poorly understood. This may be due to the slow rate 
of change of carbon dioxide tension in the cerebrospinal 
and the extracellular fluid near the medullary respiratory 
centres and other facilitory contributions of the central 
nervous system (l&20). Transferring these findings to the 
present study, it is conceivable that the increase in noctur- 
nal oxygen saturation for 1 week will influence the HCVR 
evaluated during daytime. 
Minute ventilation at rest was increased and end-tidal 
PCO, decreased in our patients when compared with the 
controls. This corroborates earlier studies on patients with 
severe congestive heart failure, where an increased minute 
ventilation with concomitantly decreased PaCO, was found 
(3,21) which is mainly due to increased pulmonary dead 
space. The increased pulmonary dead space may in part be 
attributed to a ventilation-perfusion mismatch. The other 
major factor contributing to an increase in pulmonary dead 
space is the rapid, shallow breathing due to decreased lung 
compliance and the activation of pulmonary J receptors (1). 
It has recently been suggested that a non-CO,-dependent 
central neural drive mediated by humoral factors such as 
catecholamines, a reduced blood flow to chemoreceptors 
and altered input from muscle metaboreceptors may also 
play a role (2,22). 
It is known that there is a decrease in minute ventilation 
and an increase in PaCO, when normal subjects breathe 
about 30% oxygen (23). Our results during daytime indicate 
that there is a similar increase in PaCO, with oxygen in 
patients with heart failure. Whether this increase in PaCO, 
with oxygen is in part due to an increased ventilation- 
perfusion mismatch as seen with high inspiratory oxygen 
concentrations (24) or to reduced alveolar ventilation 
cannot be derived from our data. 
Nocturnal oxygen reduces the amount of CSR by about 
50% and improves the patients’ sleep (12). As in other 
studies we found principally a decrease in stage 1 and 
an increase in stage 2 sleep, but wake and rapid eye 
movement sleep did not change significantly (12,25,26). 
This is unlikely to cause the observed alterations in HCVR, 
since sleep fragmentation or non-rapid-eye movement sleep 
deprivation have not been found to influence HCVR 
(27,28). After non-rapid-eye movement and rapid eye 
movement sleep deprivation one study described a small 
increase in HCVR (28) while another study exhibited a 
decrease in HCVR following sleep loss (29). HCVR in the 
present and other studies exhibited a high variation among 
individuals indicating important differences in individual 
chemoresponsiveness (8,30). 
Limitations 
Our patients were in a stable clinical condition throughout 
the study. However, their exercise capacity increased as 
indicated by an increase in their maximal oxygen uptake 
during exercise (12). Since the severity of heart failure may 
influence pulmonary congestion and pulmonary vascular 
pressures, alterations in the intensity of excitation of 
intrapulmonary J receptors (1) cannot be excluded. Since 
these receptors have afferents to the respiratory centre this 
might have influenced the HCVR. However, in our patients 
HCVR was not related to haemodynamic or pulmonary 
function and body weight was stable throughout the study 
period, rendering it unlikely that pulmonary congestion was 
the main factor influencing HCVR. Other mechanisms that 
may be related to the increased chemosensitivity in patients 
with heart failure include increased catecholamines, re- 
duced blood flow to chemoreceptors and altered input from 
muscle ergoreceptors (11). Also, endothelin-1, which is 
increased in heart failure, was found to be related to 
ventilatory control in mutant mice deficient in endothelin- 1 
(31). As we did not evaluate these factors, we cannot 
exclude that nocturnal oxygen influences the HCVR in part 
by these mechanisms. 
A modification of the rebreathing technique by Read (32) 
in which the rebreathing bag initially contains CO, at 
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the mixed venous level was aimed to abolish the PCO, 
gradients between the alveolar air and the chemoreceptors 
and to ensure a steady increase in PaCOZ (32,33). We 
evaluated HCVR without CO, in the rebreathing bag as 
described by Hirshman et al. (34). We used this technique 
because end-tidal PCO, was reduced and differed widely in 
our patients. The magnitude of the increase in end-tidal 
PCO, above its resting value when commencing rebreath- 
ing influences the slope of HCVR (30). Therefore the heart 
failure patients with a lower end-tidal PCO, would have 
been forced to have a higher HCVR as compared with the 
normal subjects. We also found that a sudden increase to 
7% CO, in the rebreathing bag was very unpleasant for the 
severely compromised patients and led to a rapid termin- 
ation of the rebreathing test by some of them. The different 
techniques used might explain why we found a normal 
HCVR in our patients, while Chua and colleagues, who 
used 7% CO, in the rebreathing bag, demonstrated an 
enhanced HCVR in their patients with chronic heart failure 
(11). The authors also noticed an enhanced hypoxic 
response in their patients. 
In conclusion, the moderate increase in arterial oxygen 
saturation and in PaCO, during seven nights with nasal 
oxygen reduces HCVR in patients with congestive heart 
failure. Previous studies have shown that a lower HCVR 
renders oscillations of the feedback loop controlling respir- 
ation more difficult and therefore may help to reduce CSR 
(10,35). Furthermore, a low HCVR has been shown to be 
related to less dead space ventilation, a higher peak oxygen 
consumption and therefore better exercise tolerance (11,22). 
We therefore believe that our results may have important 
clinical implications and that further studies of the long- 
term clinical effects of nocturnal oxygen in patients with 
heart failure should be undertaken. 
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